Results 101 to 110 of about 100,614 (290)

Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial [PDF]

Thorsten Oliver Goetze, Alexander Reichart, Ulli Simone Bankstahl, Claudia Pauligk, Maria Loose, Thomas Kraus, Moustafa Elshafei, Wolf O. Bechstein, Jörg Trojan, Matthias Behrend, Nils Homann, Marino Venerito, W Bohle, Michael Varvenne, Claus Bolling, Dirk Behringer, Karsten Kratz‐Albers, Gabriele Margareta Siegler, Wael Hozaeel, Salah‐Eddin Al‐Batran   +19 more
openalex   +1 more source

Treatment landscape from first‐ to third‐line therapy and quality of life data of patients with pancreatic cancer from the prospective German PARAGON (Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer) registry (IKF‐PARAGON study)

International Journal of Cancer, EarlyView.
What's New? Pancreatic cancer often is diagnosed at advanced stages. As a result, treatment regimens frequently are aggressive, with substantial side effects that impact quality of life (QoL). This study examined the treatment landscape, from neoadjuvant therapy to palliative care, in the context of QoL among pancreatic cancer patients in Germany. Most
Thorsten O. Goetze, Salah‐Eddin Al‐Batran, Ruediger Liersch, Lars Scheuer, Thomas Goehler, Ulrich Kaiser, Claudio Denzlinger, Stephan Brandl, Daniel Pink, Jens Uhlig, Michael Maasberg, Maria Loose, Marina Schaaf, Disorn Sookthai, Bianca Zäpf, Claudia Pauligk, Timursah Habibzade, Ralf‐Dieter Hofheinz, Christine Koch, for the AIO Study Group   +19 more
wiley   +1 more source

PRPF19 functions in DNA damage repair and gemcitabine sensitivity via regulating DDB1 in bladder cancer cells [PDF]

, 2023
Jingjiang Yu, Shuxiong Ge
openalex   +1 more source

Screening anticancer peptides performance in organotypic prostate tumor‐stroma 3D models

International Journal of Cancer, EarlyView.
What's New? Peptide‐based drugs have emerged as promising anticancer therapies for their potential to disrupt protein–protein interactions. In this study, the authors developed a physiomimetic human 3D prostate cancer spheroid model to assess the efficacy of the CAVPENET peptide in inhibiting tumor growth. Upon incubation with CAVPENET, prostate cancer
Bárbara Matos, Maria V. Monteiro, Matilde R. Lagarto, John Howl, Carmen Jerónimo, Vítor M. Gaspar, João F. Mano, Margarida Fardilha   +7 more
wiley   +1 more source

Clinical trial of safety and antitumor activity of farletuzumab ecteribulin in patients with platinum‐resistant ovarian cancer: Phase I expansion results

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract Objective In the dose‐escalation part of Study 101, which included multiple tumor types, objective responses were observed in 10 of 22 patients across multiple dose levels of farletuzumab ecteribulin (FZEC). We explored the safety/antitumor activity of FZEC in patients with platinum‐resistant ovarian cancer (PROC) from the Study 101 expansion ...
Kan Yonemori, Mayu Yunokawa, Koji Matsumoto, Kazuhiro Takehara, Kosei Hasegawa, Yasuyuki Hirashima, Hidenori Kato, Hiroki Ikezawa, Yohei Otake, Wataru Yusa, Takuma Miura, Shin Nishio   +11 more
wiley   +1 more source

Gemcitabine in the Era of Cancer Immunotherapy

, 2020
Katarzyna Piadel, Angus Dalgleish, Peter L. Smith   +2 more
openalex   +1 more source

Beyond a Conduit: The Evolution of Functional Biliary Stents From Active Intervention to Enabling Platforms

iNew Medicine, EarlyView.
This review traces the evolution of functional biliary stents, outlining the paradigm shift from “active intervention” strategies that target stent failure to next‐generation “enabling platforms.” These platforms leverage biodegradable materials, 3D/4D printing, and smart sensors to achieve personalized, regenerative, and theranostic solutions ...
Muhan Li, Xu Liu, Xin Ye, Zhixia Dong, Xinjian Wan   +4 more
wiley   +1 more source

Extracellular vesicle‐based vaccines and immunotherapeutics for treatment of cancer

Interdisciplinary Medicine, EarlyView.
This review highlights the innovative value of extracellular vesicles (EVs) as cancer vaccines and immunotherapy carriers. EVs have natural advantages such as low immunogenicity, high biocompatibility, stability, and precise targeting, enabling efficient delivery of tumor antigens (e.g., HER2, AFP) and immune stimulants (e.g., TLR ligands, cytokines ...
Lejia Tan, Haonan Xing, Fang Fang, Yuanyu Huang, Mei Lu   +4 more
wiley   +1 more source

RAGE inhibitors and gemcitabine: an effective combination to attenuate pancreatic cancer

, 2018
Priyanka Swami, Estelle Leclerc, Michael A. Hollingsworth, James A. Grunkemeyer, Prakash Radhakrishnan, Tom Caffrey, Prathamesh Patil, Simon Shin, Ayrianne J. Crawford, Kelly Connell   +9 more
openalex   +2 more sources

Is Micronucleus Assay a Suitable Biomarker for Evaluating the Cancer Risk in Professionals Exposed to Antineoplastic Drugs? A Systematic Review

Journal of Applied Toxicology, EarlyView.
ABSTRACT The widespread use of antineoplastic drugs in cancer treatment has led to significant concerns regarding the potential health risks posed to healthcare professionals involved in the preparation, administration, and handling of these chemical compounds, including genotoxicity.
Thiago Guedes Pinto, Lorrany da Silva Avanci, Gabriel Carvalhal de Aguiar, Daniel Vitor de Souza, Patricia Ramos Cury, Ana Claudia Muniz Renno, Daniel Araki Ribeiro   +6 more
wiley   +1 more source